| Eligo Bioscience–France (govt): investment, 202312 financing round Series B totalling $30m incl new + co-investor Bpifrance InnoBio 2 Fund |
2023-12-05 |
| Eligo Bioscience–EU (govt): grant, 201905 grant €2.8m for development of lead candidate EB003 |
2019-05-01 |
| Eligo Bioscience–BPCE: investment, 202312 financing round Series B totalling $30m incl existing + co-investor Seventure Partners HFL |
2023-12-05 |
| Eligo Bioscience–BPCE: investment, 201709 financing round Series A totalling $20m from Khosla Ventures + Seventure Partners incl $2m grant from WIC |
2017-09-26 |
| Eliem Therapeutics–SEVERAL: investment, 2019–202103 emerges from stealth with $80m in financing from RA Capital + Access Biotechnology + ICG |
2019-01-01 |
| Eliem Therapeutics–RA Capital: investment, 2019–202103 emerges from stealth with $80m in financing from RA Capital + Access Biotechnology + ICG |
2019-01-01 |
| Elicit Plant–Sofinnova: investment, 202202 equity component €na of €16m funding round incl lead investor Sofinnova Partners |
2022-02-07 |
| Elicit Plant–SEVERAL: investment, 202202 equity component €na led by Sofinnova Partners as part of funding round totalling €16m |
2022-02-07 |
| Elicit Plant–France (govt): investment, 202202 equity component €na of €16m funding round incl co-investor BPI France |
2022-02-07 |
| Elicit Plant–ECBF: investment, 202202 equity component €na of €16m funding round incl co-investor ECBF |
2022-02-07 |
| Elicio Therapeutics–SEVERAL: investment, 201910 financing round Series B $33m incl Clal + Livzon + Efung Capital |
2019-10-02 |
| Elicera Therapeutics–SEVERAL: investment, 202010 first financing round SEK13.2m share issue |
2020-10-05 |
| Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 |
2021-01-06 |
| ElevateBio–SEVERAL: investment, 202305 financing round Series D $401m led by AyurMaya Capital Management |
2023-05-24 |
| ElevateBio–SEVERAL: investment, 201905 financing round Series A $150m co-led by UBS Oncology Impact Fund by MPM Capital + F2 Ventures |
2019-05-13 |
| Element Genomics–UCB: investment, 201804 acquisition by UCB for up to $30m in upfront + short-term milestones |
2018-04-05 |
| Electrochaea–SEVERAL: investment, 202106–202201 financing round Series D €36m led by Baker Hughes + co-led by EIC Fund |
2021-06-28 |
| Electrochaea–SEVERAL: investment, 2014 financing round Series A |
2014-01-01 |
| Electrochaea–EU (govt): investment, 202106–202201 financing round Series D totalling €36m incl €14.9m from co-lead investor EIC Fund |
2021-06-28 |
| Electrochaea–EU (govt): grant, 202008 Horizon 2020 EIC Accelerator grant €2.5m |
2020-08-01 |
| Electrochaea–Baker Hughes: investment, 202106–202201 financing round Series D totalling €36m incl lead investor Baker Hughes |
2021-06-28 |
| Electrical Geodesics–Philips: investment, 201706– acquisition £29m in cash of EGI by Philips for £1.054/share ANNOUNCED |
2017-06-22 |
| Elastrin Therapeutics–Forever Healthy: investment, 202201 existent investment of Kizoo |
2022-01-21 |
| Elasmogen–SEVERAL: investment, 202205 financing round £8m led by BGF + Scottish National Investment Bank |
2022-05-18 |
| Elasmogen–Scotland (govt): investment, 202205 financing round totalling £8m incl £3.5m from co-lead investor Scottish National Investment Bank |
2022-05-18 |
| Elasmogen–Scotland (govt): investment, 202205 financing round totalling £8m incl existing + co-investor Scottish Enterprise |
2022-05-18 |
| Elasmogen–Deepbridge Capital: investment, 202205 existent Deepbridge Capital is existing investor |
2022-05-18 |
| Elasmogen–BGF (GB): investment, 202205 financing round totalling £8m incl co-lead investor BGF |
2022-05-18 |
| Eisai–Numab: antibody cancer drug, 201910– collab + license option ww excl developing multi-specific Abs using MATCH platform |
2019-10-01 |
| Eisai–Calypso Biotech: therapeutic antibody, 201703– ww license + collab for MMP-9 MAb CALY-001 with EA Pharma Co Ltd |
2017-03-31 |
| Eir Ventures–Sweden (govt): investment, 202007 first closing totalling €76m incl investor Saminvest |
2020-07-10 |
| Eir Ventures–Sustainable Development Umbrella Fund: investment, 202112 final closing with additional €46.3m of Eir Ventures I AB incl investor SDUF |
2020-07-10 |
| Eir Ventures–SEVERAL: investment, 202112 final closing with additional €46.3m of Eir Ventures I AB fund bringing total to €122.3m |
2020-07-10 |
| Eir Ventures–SEVERAL: investment, 202007 first closing €76m from Saminvest + EIF + Vaekstfonden + Novo Holdings + private investors |
2020-07-10 |
| Eir Ventures–Optimum Strategic Communications: public relations, 202007 service existent by Optimum |
2020-07-10 |
| Eir Ventures–Novo Group: investment, 202007 first closing totalling €76m incl investor Novo Holdings |
2020-07-10 |
| Eir Ventures–EU (govt): investment, 202007 first closing totalling €76m incl investor EIF |
2020-07-10 |
| Eir Ventures–Denmark (govt): investment, 202007 first closing totalling €76m incl investor Vaekstfonden |
2020-07-10 |
| Eichrom Laboratoires–Eurofins: investment, 201804 acquisition by Eurofins |
2018-04-04 |
| Egle Therapeutics–Takeda: investment, 202110 financing round Series A totalling €40m incl co-investor Taleda Ventures Inc |
2021-10-22 |
| Egle Therapeutics–SEVERAL: investment, 202110 financing round Series A €40m co-led by LSP + InnoBio 2 Fund of Bpifrance |
2021-10-22 |
| Egle Therapeutics–Life Sciences Partners: investment, 202110 financing round Series A totalling €40m incl co-lead investor LSP Fund 7 |
2021-10-22 |
| Egle Therapeutics–Fund+: investment, 202110 financing round Series A totalling €40m incl co-investor Fund+ |
2021-10-22 |
| Egle Therapeutics–France (govt): investment, 202110 financing round Series A totalling €40m incl co-lead investor Bpifrance InnoBio 2 Fund |
2021-10-22 |
| Egle Therapeutics–Bioqube Ventures: investment, 202110 financing round Series A totalling €40m incl co-investor Bioqube Ventures |
2021-10-22 |
| eGenesis–Wellington Partners: investment, 202103 financing round Series C totalling $125m incl existing investor Wellington Partners |
2021-03-02 |
| eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners |
2019-11-07 |
| eGenesis–SEVERAL: investment, 202103 financing round Series C $125m from existing + new investors |
2021-03-02 |
| eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–HBM: investment, 202103 financing round Series C totalling $125m incl new investor HBM Healthcare Investments |
2021-03-02 |
| eGenesis–Fresenius: investment, 202103 financing round Series C totalling $125m incl existing investor Fresenius Medical Care Ventures |
2021-03-02 |
| eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–Bayer: investment, 202103 financing round Series C totalling $125m incl existing investor Leaps by Bayer |
2021-03-02 |
| eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer |
2019-11-07 |
| EG 427–SEVERAL: investment, 202307 financing round Series A €5m final closing bringing total Series A to €18m |
2023-07-13 |
| EG 427–SEVERAL: investment, 202103 financing round series A €12m led by David Lamon with San Francisco based large family offices |
2021-03-01 |
| EG 427–PERSON: investment, 202103 financing round series A totalling €12m incl lead investor David Lamon with San Francisco based large family offices |
2021-03-01 |
| EG 427–Burns McClellan: public relations, 202103 service existent Burns McClellan is US media contact |
2021-03-01 |
| EG 427–ATCG Partners: public relations, 202103 service existent ATCG is EU media contact |
2021-03-01 |
| EFOS (SI)–SEVERAL: investment, 202209 financing round Series B €10m led by ECBF |
2022-09-20 |
| EFOS (SI)–Pymwymic: investment, 202209 financing round Series B totalling €10m incl existing + co-investor Pymwymic |
2022-09-20 |
| EFOS (SI)–ECBF: investment, 202209 financing round Series B totalling €10m incl lead investor European Circular Bioeconomy Fund |
2022-09-20 |
| EFOS (SI)–Demeter: investment, 202209 financing round Series B totalling €10m incl co-investor VitiRey Innovation fund |
2022-09-20 |
| Edinburgh Molecular Imaging–SEVERAL: investment, 201912 financing round £3.1m from new investor Caribou Property + existing investors |
2019-12-17 |
| Edinburgh Molecular Imaging–Optimum Strategic Communications: public relations, 201811 service existent by Optimum |
2018-11-08 |
| Edico Genome–Canale Communications: public relations, 201705 service existent by Canale |
2017-05-24 |
| Ecopro Research–Eurofins: investment, 201708 acquistion of Ecopro Research KK by Eurofins |
2017-08-10 |
| Echopoint Medical–SEVERAL: investment, 201909 financing £2.8m = investments from UCL TF + Parkwalk plus two Innovative UK grants |
2019-09-16 |
| ECBF–Volkswohl Bund: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Volkswohl Bund Versicherungen |
2020-12-15 |
| ECBF–SEVERAL: investment, 202012–202202 raising of additional €125m + final closing of fund at €300m |
2020-12-16 |
| ECBF–SEVERAL: investment, 202012 2nd closing with additional €93m from new investors bringing total to €175m |
2020-12-15 |
| ECBF–SEVERAL: investment, 201911–202010 first closing €82m from cornerstone investor EIB + 3 private investors + target size of €250m |
2019-11-29 |
| ECBF–PreZero International: investment, 201911–202010 first closing totalling €82m incl co-investor PreZero International GmbH |
2020-10-01 |
| ECBF–OTHER: investment, 202012 2nd closing with additional sum totalling €93m incl undisclosed family office as new investor |
2020-12-15 |
| ECBF–North Rhine-Westphalia (govt): investment, 202012 2nd closing with additional sum totalling €93m incl new investor NRW.Bank |
2020-12-15 |
| ECBF–Nestlé: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Nestlé |
2020-12-15 |
| ECBF–Neste: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Neste |
2020-12-15 |
| ECBF–Hettich Beteiligungen: investment, 201911–202010 first closing totalling €82m incl co-investor Dr Hettich Beteiligungen GmbH |
2020-10-01 |
| ECBF–EU (govt): investment, 201911–202010 first closing totalling €82m incl cornerstone investor EIB that has committed up to €100m |
2019-11-29 |
| ECBF–Corbion: investment, 201911–202010 first closing totalling €82m incl co-investor Corbion NV |
2020-10-01 |
| Ebenbuild–SEVERAL: investment, 202203 seed financing round €2.5m co-led by HTGF + Bayern Kapital with business angels |
2022-03-31 |
| Ebenbuild–OTHER: investment, 202203 seed financing round totalling €2.5m incl well-known business angels as co-investors |
2022-03-31 |
| Ebenbuild–High-Tech Gründerfonds: investment, 202203 seed financing round totalling €2.5m incl co-lead investor HTGF |
2022-03-31 |
| Ebenbuild–Bavaria (govt): investment, 202203 seed financing round totalling €2.5m incl co-lead investor Bayern Kapital |
2022-03-31 |
| EBAMed–SEVERAL: investment, 202306 financing round Series A €14.35m led by Panakès Partners |
2023-06-27 |
| EBAMed–Panakès Partners: investment, 202306 financing round Series A totalling €14.35m incl lead investor Panakès Partners |
2023-06-27 |
| EBAMed–Occident: investment, 202306 financing round Series A totalling €14.35m incl co-investor Occident |
2023-06-27 |
| EBAMed–Mayo Clinic: investment, 202306 financing round Series A totalling €14.35m incl existing + co-investor Mayo Clinic |
2023-06-27 |
| EBAMed–LIFIT Venture Capital Italia: investment, 202306 financing round Series A totalling €14.35m incl co-investor LIFIT |
2023-06-27 |
| EBAMed–EU (govt): investment, 202306 financing round Series A totalling €14.35m incl co-investor EIC Fund |
2023-06-27 |
| EBAMed–EFI Lake Geneva Ventures: investment, 202306 financing round Series A totalling €14.35m incl co-investor Efficient Frontier Investing |
2023-06-27 |
| Earlybird–United Kingdom (govt): investment, 202402 final closing of new Earlybird Health Fund totalling €173m incl investor British Patient Capital |
2024-02-14 |
| Earlybird–SEVERAL: investment, 202402 final closing of new Earlybird Health Fund at €173m |
2024-02-14 |
| Earlybird–Barmer: investment, 202402 final closing of new Earlybird Health Fund totalling €173m incl investor Barmer |
2024-02-14 |
| Eagle Genomics–SEVERAL: investment, 202210 scale-up financing round first close $20m led by abrdn plc |
2020-10-27 |
| Eagle Genomics–SEVERAL: investment, 202010 financing round $9m with ETF Partners + investor consortium led by Granpool II |
2020-10-27 |
| Eagle Genomics–SEVERAL: investment, 201804–201806 financing round ongoing with $1m raised until 1st May |
2018-04-01 |
| Eagle Genomics–Sarum PR: public relations, 202010 service existent Sarum PR is press contact |
2020-10-27 |
| Eagle Genomics–Granpool Innovative Investments: investment, 202010 financing round totalling $9m incl investor consortium led by Granpool |
2020-10-27 |
| Eagle Genomics–ETF Partners: investment, 202010 financing round totalling $9m incl investor Environmental Technologies Fund (ETF) |
2020-10-27 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 ... 66 67 68 ... 95 96 97 
Deal: Collaboration or Financing
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
